Not Yet RecruitingPhase 3

daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT

438 participantsStarted 2026-06-01

Plain-language summary

This study aims to evaluate the efficacy of prophylactic ruxolitinib in adult patients at intermediate-to-high risk of severe acute GvHD, as predicted by the daGOAT model.

Who can participate

Age range

16 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Age \> 16 years old.
. HLA-haploidentical transplant.
. Able to take oral medications.
. Patients must provide written informed consent before the start of the study procedures.

Exclusion criteria

. Patients who have undergone tandem transplantation or multiple transplantations.
. Patients who are allergic to or cannot tolerate ruxolitinib.
. Patients with mental or other medical conditions that make them unable to comply with the study treatment and monitoring requirements.
. Patients who are ineligible for the study due to other factors, or who will bear great risk if they participate in the study.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Severe aGVHD during 100 days after transplantation according to the MAGIC criteria

Timeframe: 100 days after transplantation

Trial details

NCT IDNCT07588945

SponsorInstitute of Hematology & Blood Diseases Hospital, China

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12-31

Contact for this trial

Yahui Feng

022-23608045 fengyahui@ihcams.ac.cn

View on ClinicalTrials.gov More Transplant-Related Disorder trials